Article
Pharmacology & Pharmacy
Peijun Cao, Qingchun Zhao, Yongwen Li, Ruifeng Shi, Guangsheng Zhu, Zihe Zhang, Hongbing Zhang, Minghui Liu, Sen Wei, Hongyu Liu, Jun Chen
Summary: In this study, a patient with locally advanced lung adenocarcinoma received neoadjuvant chemotherapy and alectinib treatment, and then underwent thoracoscopic left lower lung lobectomy. After chemotherapy, the lymph nodes enlarged again and the patient was switched to alectinib therapy, but no significant lesion changes were detected on imaging. However, the pathological findings indicated extensive necrosis in the tumor area with no residual tumor cells and massive chronic inflammatory cell infiltration, which was inconsistent with the imaging results. The possibility of intratumoral immune heterogeneity was discussed as a potential explanation for this paradoxical response.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Xiaoqian Zhai, Qiang Wu, Dan Pu, Liyuan Yin, Weiya Wang, Daxing Zhu, Feng Xu
Summary: A novel ALK fusion partner (ALK-GCA) and its sensitivity to alectinib in lung cancer were reported, highlighting the importance of detecting fusion mutations and reporting their response to guide treatment.
FRONTIERS IN ONCOLOGY
(2022)
Article
Pathology
Yijun Mo, Lina Lin, Jianhua Zhang, Yan Zhong, Tao Zhang, Chenghua Zhong, Jun Yan, Jun Kuang, Quanwei Guo, Jianfeng Tan, Dongfang Li, Mengxi Wu
Summary: This study reports a female patient with carcinoma of unknown primary site, who was later confirmed to have lung adenocarcinoma as the primary cancer through NGS. The patient initially responded well to crizotinib treatment but developed resistance after 5 months. Switching to alectinib, a second-generation ALK inhibitor, led to an excellent therapeutic response. This research suggests the use of NGS to detect ALK rearrangement in patients with carcinoma of unknown primary site and highlights the importance of considering resistance to ALK inhibitors in personalized precision medicine.
PATHOLOGY RESEARCH AND PRACTICE
(2022)
Article
Medicine, General & Internal
Weihong Guo, Jianping Liang, Dandan Zhang, Xikun Huang, Yanhua Lv
Summary: This study reports a case of lung adenocarcinoma with a rare and complex EML4-ALK fusion and a BRAF V600E mutation. The findings suggest that targeting EML4-ALK as the first-line therapy may be more effective in this particular case.
Article
Oncology
Sarang S. Talwelkar, Mikko I. Mayranpaa, Julia Schuler, Nora Linnavirta, Annabrita Hemmes, Simone Adinolfi, Matti Kankainen, Wolfgang Sommergruber, Anna-Liisa Levonen, Jari Rasanen, Aija Knuuttila, Emmy W. Verschuren, Krister Wennerberg
Summary: Treatment with ALK inhibitors improves outcome for NSCLC patients with ALK-rearranged tumors, but resistance typically develops. In this study, tumor cell cultures were generated from an ALK-rearranged tumor specimen and drug screens identified a role for PI3K beta and EGFR inhibition in enhancing ALK-inhibitor response and preventing resistance. Combinatorial treatment with ALK and PI3K beta inhibitors showed promise in targeting ALK-rearranged NSCLC.
MOLECULAR ONCOLOGY
(2023)
Article
Oncology
Mingting Wang, Yifan Gong, Yun Cheng, Lei Yang, Wenhui Wang, Xiaolin Lei
Summary: This study reported on a case of a 29-year-old male non-smoker diagnosed with both pulmonary sarcomatoid carcinoma (PSC) and lung adenocarcinoma, and identified gene fusion and high expression of PD-L1. The combination of Alectinib, Anlotinib and Tirelizumab effectively controlled the disease and alleviated the patient's symptoms. The study demonstrates the efficacy of combining targeted chemotherapy with immunotherapy for patients with PSC, and suggests the potential use of genetic testing and monitoring PD-L1 expression to select suitable candidates for this treatment approach.
Article
Oncology
Xiaoqian Zhai, Ting Wang, Yiyun Lin, Jiabi Zhang, Yuqing Wang, Weiya Wang, Qinghua Zhou, Daxing Zhu
Summary: Although previous studies mainly focused on the use of ALK-TKIs in resectable locally advanced lung cancer, this study reported a case of N3 unresectable lung adenocarcinoma that achieved complete pathological response after receiving neoadjuvant crizotinib, with no tumor recurrence found for 3 years postoperatively. This suggests the potential benefits of neoadjuvant ALK-TKIs in N3 unresectable locally advanced lung cancer.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Savvas Papageorgiou, Sarah L. Pashley, Laura O'Regan, Sam Khan, Richard Bayliss, Andrew M. Fry
Summary: Lung cancer is a common and difficult-to-treat cancer. The EML4-ALK protein has been identified as a driving factor in a subset of lung cancer cases. While targeted inhibitors of ALK have shown initial effectiveness, resistance to these drugs develops over time. This review explores the resistance mechanisms and alternative treatment options for EML4-ALK-positive lung cancer patients, including approaches that target ALK-dependent signaling pathways and combination therapies.
Article
Oncology
Qian Zeng, Han Gao, Longdan Zhang, Shouming Qin, Yongyao Gu, Quanfang Chen
Summary: The study found a patient with EGFR-resistant mutant lung cancer who developed a double-fusion EML4-ALK and STRN-ALK variant after gefitinib treatment, but a combined therapeutic regimen of crizotinib plus osimertinib showed a promising prognosis, confirmed with disappearance of some genes in subsequent genotype testing.
Article
Pharmacology & Pharmacy
A. R. Bland, N. Shrestha, R. L. Bower, R. J. Rosengren, J. C. Ashton
Summary: Cell based studies have suggested that the combination of metformin with crizotinib may enhance the killing of ALK positive lung cancer cells and overcome crizotinib resistance. However, in vivo experiments using a xenograft mouse model showed that the combination did not result in greater tumor suppression compared to crizotinib alone. Additionally, metformin did not effectively overcome crizotinib resistance or directly induce cytotoxicity on cancer cells in this study.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Oncology
Qi Liang, Huanhuan Xu, Yiqian Liu, Weiming Zhang, Chongqi Sun, Meng Hu, Yizhi Zhu, Shanyue Tan, Xian Xu, Sumeng Wang, Lingxiang Liu
Summary: This study reports a novel NBEA-ALK, EML4-ALK double-fusion in an NSCLC patient who responded well to alectinib and showed clinical benefit confirmed by liquid biopsy. The findings suggest that alectinib may be a viable therapeutic option for NSCLC patients with double-ALK fusion, and liquid biopsy can dynamically monitor treatment efficacy.
Article
Oncology
Liqun Jiang, Suping Chen, Victoria Stinnett, Lisa Haley, Laura Morsberger, Alison Shane, Melanie Hardy, Kirstin Smith, Christopher D. Gocke, Ming-Tseh Lin, Ying S. Zhou
Summary: This study identified a rare case of lung adenocarcinoma with two ALK fusions: a novel RMDN2-ALK fusion and a common EML4-ALK fusion. Multiple molecular assays were used to confirm the presence of these fusions and additional genomic rearrangements in the tumor.
Article
Oncology
Qi Sun, Qi Li, Fuping Gao, Hongyan Wu, Yao Fu, Jun Yang, Xiangshan Fan, Xiaobin Cui, Xiaohong Pu
Summary: In this study, the HER2 scoring system in colorectal cancer (CRC) was evaluated using five immunohistochemical (IHC) scoring criteria and two fluorescence in situ hybridization (FISH) criteria. The study found that the IRS-p criterion was more suitable for assessing the HER2 status in CRC patients, while the FISH scoring system could identify subgroups with unique clinicopathological characteristics.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Keiko Tanimura, Tadaaki Yamada, Koutaroh Okada, Kunihiro Nakai, Mano Horinaka, Yuki Katayama, Kenji Morimoto, Yuri Ogura, Takayuki Takeda, Shinsuke Shiotsu, Kosuke Ichikawa, Satoshi Watanabe, Yoshie Morimoto, Masahiro Iwasaku, Yoshiko Kaneko, Junji Uchino, Hirokazu Taniguchi, Kazue Yoneda, Satoaki Matoba, Toshiyuki Sakai, Hisanori Uehara, Seiji Yano, Tetsuro Kusaba, Ryohei Katayama, Koichi Takayama
Summary: This study elucidates the pivotal role of HER3 activation in the emergence of drug-tolerant cells in ALK-rearranged lung cancer, and finds that inhibiting HER3 signals combined with ALK-TKI treatment dramatically improves outcomes in ALK-rearranged lung cancer with mesenchymal features.
NPJ PRECISION ONCOLOGY
(2022)
Article
Oncology
Yuki Matsumura, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Masayuki Watanabe, Yuki Ozaki, Takumi Yamaura, Mitsuro Fukuhara, Satoshi Muto, Naoyuki Okabe, Takeo Hasegawa, Yutaka Shio, Hiroyuki Suzuki
Summary: EML4-ALK rearrangements are found in about 5% of NSCLC patients. Treatment options for ALK-positive NSCLC include various TKIs. This case suggests that switching to another second-generation ALK-TKI may be beneficial in cases of tumor progression. Further research is needed to identify markers for optimal TKI selection.
Article
Anatomy & Morphology
Mohamad Mazen Gafeer, Kareem Hosny Mohammed, Claudia Ormenisan-Gherasim, Fahad Choudhary, Momin T. Siddiqui, Cynthia Cohen
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
(2018)
Article
Anatomy & Morphology
Bradley Drumheller, Cynthia Cohen, Diane Lawson, Momin T. Siddiqui
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
(2019)
Article
Anatomy & Morphology
Catherine J. Roe, Momin T. Siddiqui, Diane Lawson, Cynthia Cohen
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
(2019)
Article
Medical Laboratory Technology
Layla Hatem, Patrick J. McIntire, Bing He, Swarna Gogineni, Mai Ho, Susan Mathew, Elizabeth M. Margolskee, Momin T. Siddiqui, Rema A. Rao
DIAGNOSTIC CYTOPATHOLOGY
(2019)
Article
Oncology
Zahra Maleki, Stephanie Muller, Lester Layfield, Momin T. Siddiqui, Natasha Rekhtman, Liron Pantanowitz
CANCER CYTOPATHOLOGY
(2020)
Editorial Material
Oncology
Momin T. Siddiqui
CANCER CYTOPATHOLOGY
(2020)
Article
Oncology
Clifton G. Fulmer, Kyung Park, Thomas Dilcher, Mai Ho, Susanna Mirabelli, Susan Alperstein, Erika M. Hissong, Meredith Pittman, Momin Siddiqui, Jonas J. Heymann, Rhonda K. Yantiss, Alain C. Borczuk, Helen Fernandes, Carlie Sigel, Wei Song, Juan Miguel Mosquera, Rema Rao
CANCER CYTOPATHOLOGY
(2020)
Article
Medical Laboratory Technology
David Kim, Susan A. Alperstein, Momin T. Siddiqui
Summary: The study found that larger volumes of cerebrospinal fluid samples lead to more precise diagnostic results, recommending an optimal volume of 8.44 mL for cytologic evaluation of malignancies. However, optimal volumes may vary based on the type of malignancy and the use of flow cytometry.
DIAGNOSTIC CYTOPATHOLOGY
(2021)
Article
Medical Laboratory Technology
Evan S. Stern, Momin T. Siddiqui
Summary: The study investigated the incidence of nuclear hypochromasia in high-grade urothelial carcinoma, identifying it in 10.2% of cases. Hypochromasia was present in 5% or more of tumor cells, suggesting it as a potential feature of high-grade urothelial carcinoma.
DIAGNOSTIC CYTOPATHOLOGY
(2021)
Review
Oncology
David Kim, Robert Burkhardt, Susan A. Alperstein, Hamza N. Gokozan, Abha Goyal, Jonas J. Heymann, Ami Patel, Momin T. Siddiqui
Summary: This study investigated the use of Z-stacked images for diagnostic assessment of urine ThinPrep WSI. The results show that Z-stack images provide minimal diagnostic benefit for urine ThinPrep WSI and do not justify the prolonged scan times and larger storage needs compared to those without Z-stack.
CANCER CYTOPATHOLOGY
(2022)
Review
Pathology
Martha B. Pitman, Barbara A. Centeno, Michelle D. Reid, Momin T. Siddiqui, Lester J. Layfield, Miguel Perez-Machado, Birgit Weynand, Edward B. Stelow, Maria D. Lozano, Noriyoshi Fukushima, Ian A. Cree, Ravi Mehrotra, Fernando C. Schmitt, Andrew S. Field
Summary: The article presents an international approach to standardized reporting of pancreaticobiliary cytopathology, developed by the World Health Organization, the International Academy of Cytology, and the International Agency for Research on Cancer. The system provides an evidence-based terminology system with associated risk of malignancy and diagnostic management recommendations. It discusses the key diagnostic features of specific lesions or neoplasms, the use of ancillary testing for diagnostic and prognostic evaluation, and implications for patient care and management.
Review
Pathology
Carla Saoud, Paul E. Wakely, Liron Pantanowitz, Momin T. Siddiqui, Syed Z. Ali
Summary: This study retrospectively analyzed the cytology findings of 10 cases of chondroblastoma and discussed the diagnostic criteria and differential diagnosis. The cytologic features included round to oval eccentric nuclei, evenly distributed chromatin, and inconspicuous nucleoli. The presence of characteristic chondroblasts allowed for a cytologic diagnosis of chondroblastoma. Cytologic evaluation should be interpreted in conjunction with clinical and radiologic findings.
Article
Cell Biology
Ivo N. SahBandar, Chandler B. Sy, Tayler van den Akker, David Kim, Julia T. Geyer, Amy Chadburn, Ethel Cesarman, Giorgio Inghirami, John Allan, Momin T. Siddiqui, Madhu M. Ouseph
Summary: We report a case of primary effusion lymphoma (PEL) in a young, relatively immunocompetent patient with no history of organ transplant receiving dasatinib for chronic myeloid leukemia (CML), BCR::ABL1-positive. We hypothesize that the loss of T-cell function secondary to dasatinib therapy may have resulted in the unchecked cellular proliferation of Kaposi sarcoma herpesvirus (KSHV)-infected cells, leading to the emergence of PEL. Cytologic investigation and KSHV testing are recommended in CML patients being treated with dasatinib who present with persistent or recurrent effusions.
Article
Oncology
Olawunmi S. Folarin, Momin T. Siddiqui
Summary: The Paris System for Reporting Urinary Cytology (TPS) is widely accepted as the standard for reporting urine cytology. This study aimed to validate the quantitation criterion of high-grade urothelial carcinoma (HGUC) in the lower urinary tract. The results confirm that a minimum of five malignant cells is necessary for diagnosing HGUC in the lower tract, with a 100% risk of high-grade malignancy.
CANCER CYTOPATHOLOGY
(2023)
Article
Medical Laboratory Technology
Susan Alperstein, Thomas Dilcher, Kartik Viswanathan, Rema A. Rao, Momin T. Siddiqui, Tamara Giorgadze
DIAGNOSTIC CYTOPATHOLOGY
(2018)